ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Sunday, October 26, 2025

10:30AM-12:30PM: Abstract Number: 0586

Immune Checkpoint agonists: A New horizon for treatment of psoriatic arthritis

(0554–0592) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0030

Immune-related Diagnoses Associated with NOD2 Variants in Human Subjects: A Phenome-wide Association Study

(0019–0048) Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 0204

Immunogenicity and safety summary for the chikungunya virus-like particle vaccine development programme

(0199–0209) Infection-related Rheumatic Disease Poster

10:30AM-12:30PM: Abstract Number: 0696

Impact of Autologous Stem Cell Transplantation on Cardiac Performance in Systemic Sclerosis

(0671–0710) Systemic Sclerosis & Related Disorders – Clinical Poster I

10:30AM-12:30PM: Abstract Number: 0072

Impact of Baricitinib on Cardiovascular Health in Biologic-naïve Rheumatoid Arthritis patients: A Comparative Study with TNF Inhibitors and Conventional DMARDs

(0067–0097) Rheumatoid Arthritis – Etiology and Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 0640

Impact of Clinically Important Improvements in Patient-Reported Outcomes on Disease Activity in Patients With Systemic Lupus Erythematosus Treated With Upadacitinib or Placebo: Results From the Phase 2 SLEek Study

(0593–0640) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0476

Impact of Comorbidity Burden on the Efficacy of, a Direct Interleukin 6 Inhibitor, Olokizumab: Real World Evidence

(0470–0505) Rheumatoid Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0075

Impact of CXCL2 and IL-11 from Rheumatoid Arthritis Synovial Fibroblasts on Angiogenesis and Endothelial Cell Network Formation

(0067–0097) Rheumatoid Arthritis – Etiology and Pathogenesis Poster

10:30AM-12:30PM: Abstract Number: 0746

Impact of Frailty on Mortality in GCA and PMR: A Retrospective Cohort

(0731–0764) Vasculitis – Non-ANCA-Associated & Related Disorders Poster I

10:30AM-12:30PM: Abstract Number: 0215

Impact of Global Review on Comorbidity Management in Inflammatory Arthritis Patients

(0210–0232) Measures & Measurement of Healthcare Quality Poster I

10:30AM-12:30PM: Abstract Number: 0343

Impact of Janus Kinase Inhibitors on Bone Mineral Density and Microarchitecture in Rheumatoid and Psoriatic Arthritis: Insights from a Real-World Cohort

(0337–0356) Osteoporosis & Metabolic Bone Disease – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 0251

Impact of Mepolizumab on Idiopathic Hypereosinophilic Syndromes: Preliminary Analysis of a Monocentric Retrospective Cohort

(0233–0279) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

10:30AM-12:30PM: Abstract Number: 0503

Impact of Olokizumab on Pain in Rheumatoid Arthritis: a Meta-analysis

(0470–0505) Rheumatoid Arthritis – Treatment Poster I

10:30AM-12:30PM: Abstract Number: 0456

Impact of Rheumatoid Arthritis on mortality and other outcomes in Heart failure: A nationwide analysis.

(0430–0469) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I

10:30AM-12:30PM: Abstract Number: 0559

Impact of Secukinumab on Cardiovascular Disease in Patients with Psoriasis, PsA, and Axial Spondyloarthritis: A Systematic Review of Existing Evidence

(0554–0592) Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].